Vericel Q1 2026: MACI momentum lifts revenue and nudges the full-year curve higher

Overview: Growth, margins, and a cash-rich balance sheet

In the quarter ended March 31, 2026, Vericel generated total revenue of $68.4 million, up 30% year over year. The company highlighted MACI revenue growth of 22% to $56.4 million and Burn Care revenue growth of 91% to $12.0 million, underscoring MACI as the primary engine of growth while Burn Care continues to contribute meaningfully to the mix.

The gross margin clocked in at 72%, a reflection of the company’s product mix and cost discipline. Non-GAAP adjusted EBITDA rose to $9.6 million, about 14% of revenue, underscoring a stronger operating leverage as volumes improve. Operating cash flow reached $16.4 million, and free cash flow was $15.1 million, highlighting meaningful cash generation even as the company navigates the usual quarterly fluctuations in a specialty healthcare business.

From a liquidity perspective, Vericel ended the period with approximately $211 million in cash and investments and no debt, creating ample runway for ongoing product development, capital allocation, and potential portfolio optimization. On the earnings line, the reported net loss was $6.3 million, or $0.12 per diluted share, a result that observers will weigh against the top-line momentum and the company’s ongoing investments in growth initiatives.

Guidance and expectations: a higher revenue forecast

Vericel raised its Full-Year 2026 revenue guidance by about $10 million, now targeting a range of $326 million to $336 million. The uplift reflects stronger early-year performance and the confidence that MACI and Burn Care momentum can be sustained through 2026. Investors will be watching how the company translates this top-line lift into continued margin improvement and free-cash-flow generation as the year unfolds.

Business highlights and structural takeaways

• MACI momentum: MACI revenue of $56.4 million represents a 22% increase, reinforcing MACI as the core growth pillar for Vericel.
• Burn Care acceleration: Burn Care revenue of $12.0 million, up 91%, demonstrates a complementary growth vector that diversifies the portfolio within the company’s sports medicine and burn care specialties.
• Operational strength: Gross margin of 72% and a non-GAAP adjusted EBITDA of $9.6 million signal improving unit economics, even as the company invests in growth initiatives.
• Cash generation: Operating cash flow of $16.4 million and free cash flow of $15.1 million highlight robust liquidity and capital-gathering capability, with no debt on the books.
• Discipline on the balance sheet: A cash and investments position of roughly $211 million provides optionality for investments in product development, partnerships, or strategic financing opportunities.
• Earnings reference: The quarter’s EPS metric shows a loss of $0.12 per diluted share, a common feature in growth-stage specialtys where investment cadence can mask near-term profitability but is often weighed against long-run cash generation and revenue expansion. Analysts may frame this against an EPS consensus to gauge any earnings surprise or alignment with expectations.

What this could portend for Vericel and its peers

Vericel’s Q1 narrative is less about a one-quarter pop and more about a multi-year rhythm where MACI anchors growth, Burn Care serves as a reliable growth accelerant, and the company uses cash to weather the investment cycle required in commercializing biologic therapies. The 72% gross margin implies a favorable mix and pricing power that, if sustained, could translate into improved profitability even as SG&A andR&D investments continue to support product development and market expansion.

From a sector perspective, the combination of strong revenue growth, meaningful cash generation, and a debt-free balance sheet sets a constructive template for peers in cell therapy-enabled franchises and specialty medicine. Higher revenue forecasts, if substantiated by continued MACI demand and steady Burn Care uptake, may elevate the bar for peers in terms of margin discipline and capital allocation precision.

Potential caveats include reliance on MACI’s continued adoption trajectory and competitive dynamics in the sports medicine and burn care landscapes. Analysts will likely monitor the pace of new customer acquisition, potential pricing changes, supply chain resilience, and how the company sustains gross margin given any shifts in product mix or input costs. Still, the early-year trajectory has a pragmatic appeal: build scale, protect cash, and let the operating leverage do the talking.

Investor takeaways and questions for the road ahead

• How sustainable is MACI’s growth trajectory, and what does that imply for revenue forecast accuracy through 2026?
• Will the company’s non-GAAP EBITDA trajectory translate into meaningful EPS accretion once scale and operating leverage are fully realized?
• What are the implications of the debt-free balance sheet for capital allocation, including potential buybacks, dividend policy, or strategic partnerships?
• How will Burn Care performance trends influence risk/return assessments relative to MACI, given their different demand drivers and competitive dynamics?
• Given the raised guidance, how might earnings surprise risk evolve if Q2 and Q3 run-rate deviates from plan, and how do analysts’ EPS consensus estimates look versus the new outlook?

Bottom line: a cash-backed growth story with a clear engine

Vericel’s first quarter of 2026 casts MACI as a durable driver of top-line growth while the company demonstrates disciplined cash flow and an attractive liquidity position. The raised revenue forecast adds credibility to the trend, and the absence of debt provides flexibility to navigate uncertainties and investment opportunities in a rapidly evolving therapeutic landscape. If MACI sustains its momentum and Burn Care continues to scale, Vericel could emerge as a steady leader within its niche—and a useful benchmark for peers watching the cash flow clock in healthcare growth plays.